Calls for FDA to prioritize human-relevant testing methods in pharmaceuticals
- Advocacy for stronger FDA guidelines
- Shift from animal testing emphasized
- Focus on human-relevant testing methods
Vanda Pharmaceuticals is urging the U.S. Food and Drug Administration (FDA) to take stronger action to facilitate the shift from animal testing to human-relevant methods in drug development. This call comes as the pharmaceutical industry increasingly recognizes the limitations of traditional animal models for predicting human responses. The company emphasizes that advancing technologies can provide better and more ethical alternatives for testing.
In a recent statement, Vanda indicated that existing regulations are not keeping pace with scientific progress. The company believes that the FDA should actively encourage the adoption of innovative testing methods that can enhance drug efficacy and patient safety. By prioritizing human-relevant testing, Vanda argues that the FDA can reduce reliance on animal models and improve healthcare outcomes.
Vanda Pharmaceuticals' initiative underscores the growing demand for more relevant and humane approaches in the pharmaceutical sector. The company hopes that heightened FDA support for these methods will lead to a faster transition, ultimately benefiting both patients and the industry as a whole.
